PTK2 and triple-negative breast carcinoma: In order to assess the potential of SJP1602 in inhibiting endogenous FAK activity within cells, we conducted an analysis of the phosphorylation of FAK Tyr397 across six cultured triple-negative breast cancer cell lines.